Kashmir, March 26,2026- The pharmaceutical sector in Jammu & Kashmir is witnessing steady growth, driven by policy support and increasing investments. As per official data, a total of 29 pharmaceutical units have been registered under the New Central Sector Scheme (NCSS) 2021, out of which 24 units have already commenced operations.
During the financial year 2025–26, these units have collectively received incentives amounting to ₹31.76 crore, reflecting the government’s push to strengthen industrial development in the Union Territory. The scheme aims to attract investment, generate employment, and boost manufacturing capacity across sectors, including pharmaceuticals.
In parallel, projects under the Production Linked Incentive (PLI) schemes for Bulk Drugs and Pharmaceuticals are also progressing in the region. Approved projects involving investments of ₹162.01 crore and ₹14.15 crore are currently underway, focusing on enhancing local production of Active Pharmaceutical Ingredients (APIs).
Officials stated that these initiatives are expected to reduce dependence on imports, improve supply chain resilience, and position Jammu & Kashmir as an emerging hub for pharmaceutical manufacturing. The development of the pharma sector is also likely to contribute to infrastructure growth and create new employment opportunities for local youth.
The government’s continued emphasis on industrial incentives and sector-specific schemes is playing a key role in accelerating economic growth and diversifying the industrial base of Jammu & Kashmir.
